Stereotactic Body Radiation Therapy for Oligoprogressive Pleural Mesothelioma: Fine-Tuning the Optimal Doses
Practical Radiation Oncology · 2024
DOI: 10.1016/j.prro.2024.05.004 ↗Kurz gefasst
Fachartikel in der Zeitschrift Practical Radiation Oncology, 2024. Verfasst von Paolo Ghirardelli und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiotherapy, Humanitas Gavazzeni Clinic, Bergamo, Italy. Hauptthemen laut MEDLINE: Radiosurgery, Pleural Neoplasms, Mesothelioma. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 8 Literaturangaben.
Abstract (Originalsprache)
There is growing evidence of a role of stereotactic body radiation therapy (SBRT) in the treatment of patients with oligoprogressive pleural mesothelioma (PM). The objective of this study was to investigate the optimal radiation therapy doses and schedules in this setting. The records of patients treated with SBRT (>5 Gy per fraction) for oligoprogression of PM at 2 institutions from June 2014 to September 2022 were reviewed. Patients were divided into 2 groups: "intermediate-dose" SBRT (i-SBRT; total dose, 30-36 Gy in 5-6 fractions) and "high-dose" SBRT (h-SBRT; total dose, 45-50 Gy in 4-8 fractions). The comparison between the 2 groups in terms of local control (LC) and toxicity was the primary endpoint of the study. Overall, 23 patients were treated for 25 pleural lesions. All had received upfront chemotherapy with platinum/pemetrexed. Fifteen patients were treated with i-SBRT and 8 patients with h-SBRT. The median equivalent dose was 40 Gy (range, 40-49.6) in the i-SBRT group and 74.46 Gy (range, 64-88) in the h-SBRT group. Six-month, 1-year, and 2-year LC were 100%, 100%, and 80% in the i-SBRT group and 100%, 100%, and 67% in the h-SBRT group, respectively (p =.94). Only 2 patients (1 for each dose group) had a recurrence in the radiation therapy field, both after experiencing a distant relapse. No severe acute and late toxicities were observed in the i-SBRT group, whereas in the h-SBRT group, 2 patients experienced G2 acute and late thoracic pain and 1 patient experienced G2 acute and G3 chronic thoracic pain. In our experience, SBRT is a safe and effective option for selected patients with oligoprogressive PM. Use of intermediate total doses keeping the dose per fraction high seems to offer an excellent LC, avoiding the risk of severe toxicity.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Department of Radiotherapy, Humanitas Gavazzeni Clinic, Bergamo, Italy.
- Radiotherapy and Radiosurgery Department, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Humanitas Research Hospital, Rozzano, Milan, Italy.
- Radiotherapy and Radiosurgery Department, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Humanitas Research Hospital, Rozzano, Milan, Italy; Department of Biomedical Sciences, Humanitas University, Pieve Em…
- Department of Medical Oncology, Humanitas Gavazzeni Clinic, Bergamo, Italy. Electronic address: giovanniluca.ceresoli@gmail.com.
Zitieren
APA
Ghirardelli, P., Costantino, G., Franceschini, D., Villa, E., Guaineri, A., Scorsetti, M., Vavassori, V., & Ceresoli, G. L. (2024). Stereotactic Body Radiation Therapy for Oligoprogressive Pleural Mesothelioma: Fine-Tuning the Optimal Doses. Practical Radiation Oncology. https://doi.org/10.1016/j.prro.2024.05.004
Vancouver
Ghirardelli P, Costantino G, Franceschini D, Villa E, Guaineri A, Scorsetti M, et al. Stereotactic Body Radiation Therapy for Oligoprogressive Pleural Mesothelioma: Fine-Tuning the Optimal Doses. Practical Radiation Oncology. 2024. doi:10.1016/j.prro.2024.05.004
BibTeX
@article{Ghirardelli2024,
author = {Ghirardelli, Paolo and Costantino, Gianluca and Franceschini, Davide and Villa, Elisa and Guaineri, Annamaria and Scorsetti, Marta and Vavassori, Vittorio and Ceresoli, Giovanni Luca},
title = {Stereotactic Body Radiation Therapy for Oligoprogressive Pleural Mesothelioma: Fine-Tuning the Optimal Doses},
journal = {Practical Radiation Oncology},
year = {2024},
doi = {10.1016/j.prro.2024.05.004}
}
EUVIMED